Robert R. Ruffolo - 10 Sep 2025 Form 3 Insider Report for LB PHARMACEUTICALS INC

Role
Director
Signature
/s/ Marc Panoff, Attorney-in-Fact
Issuer symbol
LBRX on Nasdaq
Transactions as of
10 Sep 2025
Net transactions value
$0
Form type
3
Filing time
10 Sep 2025, 19:20:39 UTC
Previous filing
20 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
RUFFOLO ROBERT R Director C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK /s/ Marc Panoff, Attorney-in-Fact 10 Sep 2025 0001187308

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LBRX Common Stock 2,365 10 Sep 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LBRX Stock Option (Right to Buy) 10 Sep 2025 Common Stock 1,792 $69.72 Direct F2
holding LBRX Stock Option (Right to Buy) 10 Sep 2025 Common Stock 717 $69.72 Direct F2
holding LBRX Stock Option (Right to Buy) 10 Sep 2025 Common Stock 10,757 $41.84 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,792 shares of restricted stock which shall vest six months from the closing date of the Issuer's initial public offering.
F2 Immediately exercisable.
F3 One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.